Cancer Research UK has announced it will study Plexxikon’s dual kinase inhibitor PLX7486 in combination with gemcitabine in advanced pancreatic cancer as part of its Combinations Alliance.<
AZ and Daiichi Sankyo announced positive top-line results from the pivotal phase 2 DESTINY-Breast01 trial of trastuzumab deruxtecan, an antibody-drug conjugate, in patients with an advanced
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh